text:
Written by: Terry Link
Primary Source : Possibilitator, November 13, 2015
This is the text of a talk presented today for a Faculty Forum at Michigan State University. I dedicate this talk to our colleague Bonnie Bucqueroux who left us suddenly and too early. Bonnie, we're trying to carry your load. Your inspired life keeps us going. Be Kind. Be Connected. Be Unafraid.
What is striking about this conceptual journey that the idea of the university has undergone – over nearly one thousand years – is that it has gradually shrunk. Whereas the metaphysical university was associated with the largest themes of humanity's self-understanding and relationships with the world, the idea of the university has increasingly – and now especially in its entrepreneurial and corporate incarnations – closed in. The entrepreneurial university is expected to fend for itself, and attend to its potential impact on particular segments of the economy, and become distinctive. This university has abandoned any pretense to be associated with universal themes.
The idea of the university has closed in ideologically, spatially and ethically. Ideologically, the contemporary envelope of ideas encourages the university to pursue quite narrow interests, particularly those of money (in the service of a national – or even a global – knowledge economy); spatially, the university is enjoined to engage its region, especially with industrial or business organizations in its environs (increasingly its students are also 'local'); and ethically, the university has become focused on its own interests. It will, as a result, close departments of chemistry or physics or modern languages or philosophy because it sees such closures as serving its own (usually financial) interests rather than their being laced in a set of public interests. (pp.1-2) Ronald Barnett. Imagining the University. London: Routledge, 2013
What we see if we peek over the wall is the possibility of a world in which our capacities to care for ourselves and others will increase only if we have the courage to admit that we need, and will benefit from, recognizing the large web of caring relationships within which our lives gain meaning.
There is a way to turn our world around. It requires us to recommit to caring for ourselves and others by accepting and rethinking our caring responsibilities and providing sufficient resources for care. If we are able to do this, then we will be able to enhance levels of trust, reduce levels of inequality, and provide real freedom for all. In such a society, we would have to conclude, with Giambattista Vico (1990): "What is justice? It is the constant care for the common good."
I say all this to you because hope is not like a lottery ticket you can sit on the sofa and clutch, feeling lucky. I say this because hope is anax you break down doors with in an emergency; because hope should shove you out the door, because it will take everything you have to steer the future away from endless war, from the annihilation of the earth's treasures and the grinding down of the poor and marginal. Hope just means another world might be possible, not promised, not guaranteed. Hope calls for action; action is impossible without hope. At the beginning of his massive 1930s treatise on hope, the German philosopher Ernst Bloch wrote, "The work of this emotion requires people who throw themselves actively into what is becoming, to which they themselves belong." To hope is to give yourself to the future, and that commitment to the future makes the present inhabitable. –
Latest posts by Terry Link (see all)
- Beginnings and Endings - October 29, 2019
- Enough Already!! - April 18, 2019
- Attitude of Possibility - March 1, 2019


text:
Less than a year ago Francis Ngannou was being praised by the UFC and promoted more prominently than former UFC heavyweight champion Stipe Miocic. Today, Ngannou is sitting on two consecutive losses while serving as the butt of many jokes in the MMA community. So you wanna be an ultimate fighter?
The Camaroonian-French fighter ended 2017 with one of the most vicious knockouts in MMA history against Alistair Overeem. Unfortunately, 2018 hasn't been as kind to Francis Ngannou. Going from Just Bleed to Just throw a punch in a short period of time is no fun. The only logical response is to kick him while he's down. During last week's interview on UFC Unfiltered, Dana White held no punches when addressing Ngannou's latest performance against Derrick Lewis at UFC 226.
"I believed this guy was going to be the heavyweight champion and he lost his mind. This guy completely lost his mind. He started to act in a way you just don't act. I completely saw it coming …" He continued. "Francis Ngannou left the training center, took off to France, was in France training or doing whatever he was doing leading up to the Stipe fight because he absolutely, positively knew he was going to beat Stipe."
White then addressed Ngannou's latest performance.
"As you can tell both guys were gun shy. The beast said his back was messed up during that fight … Ngannou has got a lot of things he needs to fix personally and professionally to see if he ever gets back on track again."
The UFC always seem to run into the same problem in regards to picking favorites. Said favorites can't help but buy into their own hype and become overconfident as a result. Ronda Rousey springs to mind. Fortunately for her, uncle Dana refrained from throwing stones Rousey's way following her downfall. As for Ngannou, it was only 8 months ago that he was receiving the promoter's push towards UFC gold.
The UFC wasted little time in capitalizing on the "Predator's" popularity and booked him for a title shot a little over a month following his win against the "Reem." The result was a humbling experience and the average fan's perception was that Ngannou was the latest victim of the UFC hype train.
And there is nothing fans love more than watching fighters who the UFC are clearly behind, lose in embarrassing fashion. It's a rough sport, inside and outside of the cage, but somebody's gotta do it. Ngannou's performance against Lewis turned MMA's biggest puncher into its biggest punchline.
Funny enough, Ngannou has received more flack than his counterpart. Lewis was smart enough to have an excuse for his performance. He also came away with the win through the eyes of the judges. And now, he finds himself once again as the co-main event on a big UFC pay-per-view card, probably the biggest of the year. Ngannou on the other hand is now fourth in the UFC's heavyweight rankings behind Curtis Blaydes, who he defeated two years ago.
Better luck next year. After all, the UFC's current favorite heavyweight is receiving a title shot coming off two losses. Because doing steroids is worse than underperforming.

subset: commoncrawl


text:
Hey all! So a few people actually wanted to guest blog for The Binge. Imagine that!
I'm calling this feature "Guest Writer" because that's how I imagine a person would say "Ghost Writer" (remember that TV show?) in a weird Dutch accent. And because there's a guest writer.
Today's guest post come from Emily. She is a professional communicator in marketing and public relations, most recently for the produce industry. She also likes to exercise outdoors. Like, running in canyons. So she is legit on many levels. Funny enough– while I reside in LA and often visit Old Towne Orange, Emily lives in Old Towne Orange (with her husband, Damian) and often visits LA. She is also a frequent Yelp commenter.
For her first guest post, Emily reviewed an eatery that's new to Old Towne/The Circle and has proven to be the Pink's of Glassell Avenue… a tiny waffle stand that's making a big splash. I'm stealing all these pictures from the Googles. If you click them you'll see where I stole them from. (And I'm writing the captions– don't blame Emily.)
OH and I just found out that today is Emily's birthday. Happy birthday!!! (This is your present?) (Sorry.)
My husband and I tried Bruxie for dinner. We live local and we always try what pops up in downtown Orange.
On this cold, windy night, we hopped on down the street. We discovered a decent sized crowd. I didn't expect a line on their Grand Opening Day– and who knew the line would continue all these many months later.
Here are our first impressions:
Presentation: Cute upgrade to the location with the paint colors, signage, and tables. The branding is simple, chic and clean. Although the tag line "The Bold Fold" makes my husband think of the female anatomy. [Ed. note: I like him already!] Good or bad…it is memorable. We don't have to worry about parking, but we know it to be limited and must be a struggle for a new business. However, with Chapman University nearby, we can see it being a lunchtime favorite that is easy to walk to.
Service: The line was long and slow. We didn't really see that as a problem being that Bruxie has just opened and probably wasn't anticipating the rush, which also reveals why they were out of the Chicken and Waffle Sandwich and the Bacon, Egg and Cheese Sandwich. There was a very helpful person delivering completed orders and answering questions. I would be happy to hire her for any service job as she was friendly, prompt, and cute.
We thought it was weird that the waffle fries came out first. Then 10 minutes later the custard came out, and then finally, the sandwiches a few minutes later. It would have been nice to get everything at once to keep what needed to be hot, hot and what needed to stay cold, cold.
Waffle Fries: We enjoyed the fries immensely. They were hot, crispy and delicious. We didn't even need ketchup with them. [Ed. note: Whaaaat?] We ate them before anything else could arrive.
Bruxie Burger: We found that the waffle worked really well with the burger. It gave the sandwich an unexpected crispiness and was not really sweet at all to distract from the flavor of the burger. The burger was meaty, juicy and not overcooked. The tomato and lettuce were very fresh. The only thing that could have improved it was some of the tasty cheese that you can get when you order a Cheesy Bruxie.
Sun-dried Tomato and Goat Cheese: Not worth the money at all. I love this combination of flavors normally, but it was overpowered by the waffle. There was not nearly enough sun-dried tomato and there was no indication of the balsamic reduction. This was just a fold. There was very little filling. I think this is the challenge with "The Bold Fold." I gave more than half of it for my husband to eat because I didn't want to waste my calories.
Having returned a few times, I would recommend other items on the menu because I haven't had a bad eating experience since the Sun-dried Tomato and Goat Cheese fold. I recommend the Bacon, Egg and Cheese Bruxie, the Prosciutto and Cheese… the list goes on.
I enjoy that they have seasonal menus as well, hand-written on a chalkboard. The Chicken and Waffle was good, but I would not order it again. However, I would order the Bacon, Egg and Cheese again and again. It was delicious morning, noon and night. We have even taken my in-laws. Despite the enormously long line, they loved it and have Facebooked us with comments about it.
I have also been very impressed whether it is a Grilled Mushroom Bruxie or a Fresh Strawberry shake. I will even throw in loving any of their Crème Brule sweet Bruxies. We still need to try many of the sweet waffles to be fair, but we know Peet's coffee is available there and is great.
Custard: I wasn't a huge fan of the custard. I think you can get a better tasting value with frozen yogurt. That said, it was very creamy and my husband thought it was very tasty and rich, but he felt it could use some hot fudge or butterscotch.
We believe Bruxie has surpassed its potential in downtown Orange. Since the Grand Opening, it has worked out a lot of its first day kinks. Our suggestions would be…
-Let the poor girl delivering food and announcing numbers be there for questions and clean up and get a PA system to announce numbers.
-Save yourself some labor and have the customers pick up their stuff. It will save you some trouble and customers are used to being called up for fast food at a window. (That said, this isn't really a ding as the staff is very friendly and whatever ways works for them ultimately works for me. It is very nice that you get table service in a fast food setting.)
– Call the order when everything is done and not one item at a time. It would have been nice to have the fries with the sandwich on our first trip. However, not really a ding either because I really feel this is improving as well.
We have also observed many other changes since the first opening like lights for the sign and covering and umbrellas from inclement weather. I wonder how much profit is being made at this tiny gourmet stand… incredible success from an outside perspective.
Thanks, Emily! You can read more from Emily on her blog, her… other blog, her Yelp, or her Twitter.


text: That site wants to access all of your face book information. I am actualy kind of new to facebook and I was doing something earlier today and it said login using face book. OK that will save some time, then it wanted to access all of my contacts and everything. No thank you!:mad:


text:
A new Monday Mix which takes in the exotic deepness of Japanese jazz legend Kazumi Watanabe; a piece of seminal cosmic afro from 1976 by Ozo; and some Jamaica meets Morocco vibes from Bob Fadoul. As always we dip in and out of an array of genres from all over the musical globe TS style. It's all good music! Check out the tracklisting and make sure to follow us on SoundCloud, Mixcloud and Tumblr for more music. Press play, download and happy listening.
1. Skxtchy AP – SpaceCruise
2. D.K. – Leaving
3. Kazumi Watanabe – Garuda (Kuniyuki Remix)
4. A Vision of Panorama – Open Sequence
5. Ozo – Anambra River
6. Throwing Shade – Wonderful Sushi
7. White Magic Cult – Triángulo del Silencio
8. Cropper & Dross – Jaxa
9. Tom Trago – Voyage Direct
10. Atsushi Yano – Fat Tail
11. Fadoul aka Bob Fadoul – Fi Jamique
12. Tutu Atrash feat. Tsvia Abarbanel – Jaja Nights
13. Mugwisa International Xylophone Group II – Jinja Pearls
14. The Munaana of Mugwisa (Ishmael at the Controls)
15. Penya – Acelere (Jose Marquez Remix)
Follow Lina's super Instagram account @ https://www.instagram.com/flower_lina


text:
By Jardine Malado
The Christian Times (23.10.2017) – http://bit.ly/2h3yQrp – Port authorities in Sudan have detained a shipment of Arabic Bibles for two years without providing an explanation, according to a representative of a Bible society.
The representative, who wished to remain anonymous, told Morning Star News that a shipment of Arabic Bibles that was headed for Sudan's capital of Khartoum has been detained by authorities in Port Sudan for more than two years.
Due to the delay in the release of the shipment, the Bible Society in Sudan still does not have a single copy of an Arabic Bible available in Khartoum, the source said.
Another container with Arabic Bibles was also withheld, but it was released shortly after appeals to port authorities.
The source further noted that other shipments of Bibles have been detained at Port Sudan, on the Red Sea, over the past two years.
Other international organizations that provide Bibles have also complained about the detainment of shipping containers full of Bibles. Most cases have been attributed to corruption, but some cases are believed to be attempts to keep the Judeo-Christian scripture out of the country.
The representative of the Bible society pointed out that the detainment of Bibles in Sudan also took place before 2011, with one shipment held up for almost four years.
Christian leaders have speculated that Sudan may be open to releasing the shipment after the U.S. government lifted the sanctions against the country on Oct. 12. Sanctions have been placed against Sudan since 1997 due to its terrorist ties and violations of human rights.
According to the representative, a port official has recently indicated willingness to consider releasing the shipment.
Following the secession of South Sudan in 2011, Sudanese authorities launched a crackdown on churches and Christian literature, on the pretext that most Christians have fled the country after the separation.
In 2013, the Sudanese Minister of Guidance and Endowments announced that it will no longer grant new licenses for the construction of new church buildings, citing a decrease in the South Sudanese population.
As many as 25 churches in Sudan have been designated for destruction earlier this year. On May 7, a church building, which began as a refugee camp for South Sudanese, was demolished in the Khartoum suburb of Soba al Aradi. On Aug. 2, a Baptist church in Omdurman was demolished by the authorities.
The government has maintained that the churches were built on land that was intended for residential or other use, or were on government land, but church leaders have suggested that it was part of a wider crackdown on Christianity.
Sudan has been designated by the U.S. State Department as a Country of Particular Concern since 1999, due to its treatment of Christians and other human rights violations.
If you want to be regularly informed about different violations of human rights in the world, click here for a free subscription to our newsletters!
HRWF database of news and information on over 70 countries: https://hrwf.eu/newsletters/forb/
List of hundreds of documented cases of believers of various faiths in 20 countries: https://hrwf.eu/forb/forb-and-blasphemy-prisoners-list/


text:
TVI -Transport video interface (PoC)
This enables video and power to be run over single coax cable. Existing coaxial cable is usually compatible so older systems can be upgraded. PoC offers great value and quality.
PoC system basics
We sell to the public and trade (prices on request).
We also install CCTV security systems in domestic and commercial premises.


text:
The Community Foundation is proud to work with a variety of stakeholders to creatively and collaboratively advance high priority initiatives in our region, such as the current development of a citywide system of out-of-school time programs for Richmond City students. In partnership with several individual donors, the Community Foundation recently funded a new Out-of-School Time Systems Coordinator to work with foundations, program providers and the schools to facilitate their efforts to better serve children and families who otherwise may not have an opportunity to participate in quality afterschool and summer programming.
We are pleased to introduce you to Shanelle Ebanks, who stepped into the Out-of-School Time Coordinator position in April. We sat down with her to learn more about her passion for youth development and her new role.
What sparked your interest in youth development?
I've worked with kids in some capacity my entire life. In college, I had the opportunity to help structure an afterschool program. Even though I was taught about traditional things like curriculum and classroom behavior management strategies, the aspects I wasn't fully prepared for were the things that affected my kids before they got to school, afterschool or in the community.
For example, regularly struggling to provide my kids with a basic afterschool snack while million-dollar homes were being built across the street from the community center. How do you instill worth in a child when the stark contrasts of the gentrification they are living in tells them otherwise? Or, how do you support a child whose parents are going through a divorce and during fights, dad would take the son and drive around until 2 or 3 a.m.? There was no way he was ready and fully present to learn the next day, and he just slept through afterschool. We're putting kids in situations where we want them to learn, but there's so much that affects their ability to do so above and beyond curriculum.
I wanted to learn more about the systems that affect kids and their learning, beyond what happens in the school building. I participated in a fellowship in a low-income private school in Hyderabad, India and had the privilege of witnessing the influence of women's rights, corruption, politics, religion, culture, and so much more — you see, in the best and worst ways, all these things shape our kids.
Coming back from India, I knew I wanted to further my understanding of systems that affect our families and youth. I received a Masters from N.C. State with dual concentration in Volunteer Management and Administration and Youth Development Leadership, which has allowed me to answer big questions about the work that I do.
You recently organized citywide youth initiatives in Hopewell as the Office on Youth Coordinator. Can you tell us something you took away from that experience?
One of the things I'm really proud of is helping community members see themselves as part of the solution. Often, the viewpoint I got was, "I'm not a teacher, so I can't help kids," but everyone has something to offer. It's just a matter of getting them placed in the right circumstance where they can thrive and where our kids can gain the most benefit from the experience.
Describe your role as the Out-of-School Time Systems Coordinator.
There are a number of key partners throughout the city who have identified out-of-school time programs as a great opportunity for growth — not only for our youth and our families, but for the city as a whole. My role is to bring together those partners and cultivate relationships between them, and to help design a system that supports all stakeholders in the process. I'm working to have our funders, out-of-school time programmers, the schools, our youth, and their families all see themselves in the system and have their needs met. Through this process, we can help prepare our youth, not only for the transitions of school years but also to the ultimate goal of being successful, contributing members of society.
Why invest in out-of-school time?
Everyone thinks about education as during the school day, but there's so much of who you are as a person that happens outside of those hours. We have a chance to help kids be who they are, find their voice and connect with their purpose and their passion. Every person has value and can contribute something, so how can we get them connected to the thing that gives them the most joy and that allows them to contribute in the best way possible?
We also have the opportunity to reinforce what happens during the school day, and we know statistically that out-of-school time programs can improve school attendance and grades, and they have a great impact on behavior, confidence and self-esteem, among other outcomes.
As we look at the landscape and are honest about changing family structures, we absolutely need more support for our kids. Regardless of one's family dynamics, it takes a village to raise a child. Who's to say that you can't have more people in your village? The more positive influences, experience and exposure that our kids get, the more well-rounded, confident and capable they become.
3409 Moore Street
Richmond, VA 23230
P.O. Box 76495
Baltimore, MD 21275-6495
(804) 330-7400
Email Us
© Sitemap | Conditions & Policies


text:
Viktor Koen
Science remains institutionally sexist. Despite some progress, women scientists are still paid less, promoted less,win fewer grants and are more likely to leave research than similarly qualified men. The reasons range from overt and covert discrimination to the unavoidable coincidence of the productive and reproductive years.
In this special issue, Nature takes a hard look at the gender gap and at what is being done to close it. A survey of the data (see page 22) reveals where progress has been made and where inequalities still lie, from salary to tenure. A News Feature (see page 25) reveals a particular dearth of women in some commercial spheres, such as on the scientific advisory boards of biotechnology firms, and an article by historian Patricia Fara (see page 43) traces the wearying stereotypes perpetuated by the biographers of women scientists.
A series of Comment articles looks at possible solutions. Neuroscientist Jennifer Raymond (see page 33) calls on both sexes to recognize and reduce their biases against women in science, and eight researchers from around the world offer their prescriptions (see page 35), from equalizing the retirement age in China, to liberalizing travel restrictions in Saudi Arabia, to boycotting conferences that lack female speakers. We catalogue some of the ambitious moves being made in Europe to get more women into top positions (see page 40) and explore some surprising statistics about mandatory quotas (see page 39). Finally, profiles of four successful 30-something women (see page 28) show how ambition and talent can trump obstacles.
This special issue is dedicated to the memory of Maxine Clarke. In the 28 years that Maxine spent championing the highest scientific standards as an editor at Nature, she was all too often the only one to ask, "Where are the women?"
- Journal name:
- Nature
- Volume:
- 495,
- Pages:
- 21
- Date published:
- ()
- doi:10.1038/495021a


text:
The 2017 Rip Curl Cup is officially on "High Alert" to be held on Thursday, July 27th at Padang Padang. With an impressive SW swell currently tracking towards Bali, event directors have changed the official event status to "Amber" and surfers are now on high alert for a Thursday, 7 AM local start time to run the one-day WSL specialty event.
Official event surf forecaster Surfline is calling for a long period SW swell (235-220°) to build in late Wednesday through Thursday, coming from an ideal angle to catch the reef at Padang Padang. This run of swell could potentially provide up to three days of contestable conditions at Padang for event organizers to choose from.
"We expect sets around the double overhead zone (8-12' faces) at Padang Padang on Friday, with occasional larger waves, especially during the better tides. This size holds strong all day and through Saturday." – According to Surfline
Event directors will be ready to run early Thursday morning in the event the swell peaks earlier than predicted.
Most of the 16 invited surfers – 8 of Indonesia's best and 8 of the world's top tube riders – are currently standing by on Bali's Bukit Peninsula, preparing to catch this swell. The remaining invitees are already on their way to Bali or preparing to board flights.
The 2017 Rip Curl Cup Padang Padang will be webcast live to the world at ripcurl.asia. Fans can also visit the site to check the latest Padang Padang swell forecast from official event forecaster Surfline, real-time contest status, and video updates from Bali.
Event Waiting Period – July 10th – Aug 10th


text:
The Health Ministry yesterday said the dengue fever situation in the Kingdom is under control with fewer cases detected this month.
However, it warned that the situation could worsen during the current phase of a 10 to 12-year epidemic cycle in the Asia Pacific region during which 303 people in the Philippines and 74 in Malaysia have died from dengue-related diseases. The last cycle was in 2007.
The ministry noted in a statement that from the beginning of the year until July 1 there were 15,000 dengue fever cases with 25 deaths in the Kingdom.
It called on all authorities in the capital and provinces to urgently carry out dengue prevention measures, including identifying Aedes mosquito breeding sites and spraying pesticides to kill their larvae in high-risk areas.
"As a result of such measures carried out over the past 30 days, the Ministry of Health has observed that dengue fever is now under control and dengue fever cases have decreased in 11 provinces from previous months," the statement said.
It noted that Pursat, Takeo, Stung Treng, Svay Rieng, Ratanakiri, Pailin, Koh Kong, Kampong Thom, Battambang, Preah Sihanouk, Mondulkiri, Kratie, Kampot, Prey Veng and Kep provinces had not reported any new case of the disease.
The ministry reiterated its call to the public and authorities at all levels to implement preventive measures such as getting rid of larvae breeding- grounds inside and outside homes by not allowing water
to stagnate in vessels such as jars and basins and also puddles. The statement said health department officials should also spray pesticide in potential breeding areas and that items such as used tyres, bottles, cans and coconut shells, which can collect water, should either be buried or burnt.
It urged dealers to discard used tyres properly because these were the biggest source for mosquito to breed, noting that construction sites should also take steps to clear debris which can collect water for the insects to breed.
"In case of a severe fever, immediately take the person to the nearest public healthcare centre [no later than 72 hours after the fever] or hospital," the statement said. "Do not try to treat patients at home."
"Dengue fever can kill patients who are not treated professionally on time," it added.
Cheam Chan Sophorn, Tboung Khmum provincial governor, yesterday urged residents to immediately take those suffering from high fever to the nearest health centre for treatment and avoid consulting private practitioners or village traditional healers.
"Provincial health officials have been going to the ground to educate the community that dengue fever is very dangerous and can only be treated by health professionals if the patient is sent to the health centres or hospitals in time," he said.
- Tags: dengue fever, Health Ministry, mosquito


text:
3rd Power Dream 40 American Head and Dream 112 Gold Cabinet Stack - Ivory/Black
3rd Power Dream 40 American Head
3rd Power's DREAM 40 AMERICAN amplifier takes the American channel of our Dream Weaver MKII and packs it all into a smart, streamlined package. You'll be amazed by DREAM 40 AMERICAN's crisp performance with superior precision, consistency and beauty.
Inspired by our very own Dream Weaver MKII, the Dream 40 American takes both Tweed and Blackface voices and packs them into this single channel amplifier.
Channel Strip Close Up
Two different vintage American preamp voices are available via toggle switch, including Tweed (based on a '59 tweed bass amp) and Blackface (based on a '63 blackface bass amp). When you select your sound, you are switching entire preamp and tone stack circuits that faithfully recreate a superb vintage vibe. Blackface mode delivers that classic "scooped mid" American sound with excellent headroom. Tweed mode has that meaty "mid growl" and sweet top end that just oozes with vintage "voodoo."
Tube Rectification
For the ultimate experience in the "feel" department, we built in a rectifier tube socket loaded with a GZ34 tube rectifier for a vintage "tube sag" that adds just the right amount of compression and bounce to your sound.
HybridMASTER Volume Control
HybridMASTER and the Venue Switch are located on the front panel giving you the confidence to play what you feel when you feel it at exactly the volume you need for the occasion. Think of the Venue Switch as a "macro" volume adjustment - choose between full volume (Stage Mode) or an 80% volume reduction (Studio Mode), and the HybridMASTER knob as a "micro" volume adjustment allowing you to fine tune your output levels. Patent-pending, HybridMASTER is volume management executed to perfection.
3rd Power Dream 112 Gold Cabinet
3rd Power's DREAM SERIES speaker cabinets are sonically and visually refined. They deliver a full-bodied frequency response that is well defined and in control throughout the frequency spectrum of your guitar tone. With its patented triangular speaker chamber, the DREAM SERIES 112 is the perfect choice when you want your sound to translate in the mix.
Refined Tone with an Extra Kick
The design goal for the DS112 was to capture the enormous spirit and sonic footprint of its' big brother, the DS212 cab, but pack it all into a convenient 112 package. Well, we nailed it.
Patented Design
Crafted from 5/8" birch, the DREAM SERIES 112's features an embedded triangular speaker chamber to eliminate standing waves and internal reflections. With construction features including increased cubic volume and a tuned triangle port, the DS112 delivers your full frequency response with a detail and punch that sounds more like a mastered record and won't get lost in the mix.
Extended Low Frequency Response
Extended Internal Dimensions
With an interal area of 1.94 cuFT, the new DS112 boasts a 35% increase in total cubic volume compared to our original SB112 cabinet. That translates into a noticeably huge sound.
Triangle Ported Back Panel
To refine the tuning of the cabinet, we brought back our triangle ported back panel. We experimented with size and port placement until we got exactly the response we were looking for. The frequency response is extended just right: balanced when on the bridge position pickup, and with a noticeable punch and kick when on the neck position.
N Stuff SKU:
3rd Power
|Model Name:
|Dream 40 American
|Class AB, 40 Watts (tube rectified)
|Power Tubes:
|Tungsol 6L6 x 2 as standard
|Preamp Tubes:
|V1 - 2: JJ Electronics ECC83S, V3: Sovtek 12AX7 LPS
|Channel Controls:
|Volume, Bass, Treble and Blackface/Tweed switch
|Other Controls:
|Presence, Stage/Studio Output Mode Switch (Stage Mode = 100% output, Studio Mode = 20% output), HybridMASTER Level Control for Fine Tuning Output Level, Insert-style FX Loop
|23 lbs.
|Case Composition:
|5/8" Birch
|Speaker Outputs:
|1 x 16, 1 x 8 and 1 x 4 Ohm Speaker Outputs
|18" x 10" x 9.33"
|Operating Voltage:
|120V is standard. Export 240V and other mains voltages are available
|Rectifier Tube Socket:
|One Rectifier Tube Socket: Socket ships loaded with GZ34 Rectifier Tube
|CE Certified
|Model Name:
|DS112 - Gold
|Power Handling:
|60w loaded with a Celestion Alnico Gold
|49 lbs
|25" x 20.75 x 11"
|5/8" birch enclosure, 1/2" birch internal chamber, dado joinery throughout
|8 ohms


text:
Varilight 3-Gang 2-Way Push-On/Off Rotary LED Dimmer 3 x 0-120W
Product code: VAJDCDP303S
Catalogue page:
Next day delivery subject to stock availability. Order by 3 pm.
How Can we Help?
- 3 gang 2-way push on/off rotary LED dimmer
- 3 x 0-120W V-Pro intelligent dimming technology
- Includes a soft start feature and overload protection
- Adjustable minimum brightness setting and choice of drives modes
- Finish: Polished Chrome
- Chrome Knobs
- Dimensions: 86x147x48mm
- Faceplate Depth: 4mm
- Product Weight: 380g
- Fixing Centres: 120.6mm
- Recommended Back Box Depth: 35mm
- Operating Voltage: 220/250V AC
- Maximum Load Rating: LED; 120W (Halogen; 250W, Mixed Loads; 120W) (Max. 10 lamps for all lighting types)
- Maximum Current Rating: 1.1A
- Terminal (Live) Diameter: 3.2mm; Capacity: 3 x 1.5mm²
- Terminal (Earth) Diameter: 3.3mm; Capacity: 3 x 1.5mm²
- Applicable Safety Standard: BS EN 60669-2-1
- Code: VAJDCDP303S


text:
I recently met a girl who was a bride last year, and told me a horror story of how she had hired a photographer without any prior contact – it was a matter of going into an office and signing her memories away. When she received the photos she wept and hasn't looked at them since!
I nearly wept myself.
I wanted to write some helpful tips for brides & grooms who will be looking to find 'the one' – the photographer who encapsulates their special day – every emotion, colour and thought into a visual artistry documented especially for them in the form of photography.
Over the last few years I have encountered a number of horror stories, so much so that I just had to blog about it.
The only reoccurring problem was that there had been no consultation before the wedding to see if there was a connection, to discuss the big day in more detail, to ask questions from the photographer or for the photographer to get to know the couple's story in more detail. All of these are crucial to how any good photographer will capture you, understanding one another is paramount to the couple feeling like they were understood and that their personal relationship shines through when they flick back through the album. Also, the photographer will get a better grasp on how to tailor their style for your needs.
In the grand scheme of things, when you're planning a wedding this may seem like a 30 minute coffee (or cake if you're me) you can miss with the big day approaching.
Despite many photographers and couples being separated by oceans, mountains and in the UK – traffic, we have modern technology. If I can't get to a bride in person, there is a multitude of live chats and failing that, a phone call is better than nothing.
These are 5 things you & your photographer should discuss at your consultation
(in my humble opinion);
1. A little about them. Don't be shy to ask – you want a photographer who loves what they do (I have met a few who don't and it was very obvious to everyone – not a great look).
2. Details. The plan of your day, details of the venue and a general overview. Planning is important to ensure the day goes smoothly.
3. Your story. Give a little or a lot, it goes a long way in how a photographer will feel they can depict you and see what you'll be comfortable with when for e.g. you're doing the couple shots away from the main wedding.
4. Albums. Ask to see one in person, size is not so imperative, quality is. Whilst images on a disc are lovely to look at, there is nothing like carefully lifting the pages in a beautiful album and glowing from within a few years down the line. If you want to have a look at a whole range, ask them to email you pictures, different sizes and finishes so you can think about it.
5. The shot. If you haven't already studied the photos on the website (which by the way is very naughty!), or wish to see them again point out the ones you particularly love! This massively helps both the photographer and you as a couple. The photographer will remember what specific shots you like, e.g. quirky shoe shots and details that on the day you may overlook.
At the end of the consultation you should feel excited, happy and as if you've just made a friend.
If this hasn't happened- find the nearest exit.
I hope that helped those of you who have confided in me to spread the above advice, and those who hopefully will never have to confide in me about such matters, (I found just writing about it therapeutic)!
Thanks for popping by!


text:
Blake's six damage car at cricket match
Double Olympic Games silver medallist Yohan Blake returned to action in his favourite sport - cricket - on Saturday and helped his team Bartley's XI to a 36 - run win over the Correctional Services in the Sherwin Williams-sponsored St. Catherine Twenty20 cricket league here at the Prison oval.
Blake, who came out at number 5 in the batting order, started off slowly while stroking few singles on both sides of the pitch. However, in the last three overs, he went on the attack, which brought about one of the game's biggest sixes, which damaged the back glass of a car parked outside the small ground. Blake went to inspect the damaged car where he was greeted with a hand shake by the owner, who told him "it's part of cricket."
He went on to make 20 off 21 balls before falling to the last ball of the innings when he chipped at a ball and missed only to be stumped by the wicketkeeper.


text:
Adrian Bot
Vice President of Translational Medicine
Kite, a Gilead Company
Adrian Bot, M.D., Ph.D. is the Vice President of Translational Medicine at Kite, a Gilead Company, developing genetically engineered cell products for oncology indications. Dr. Bot obtained his M.D. in Romania in 1993 and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998. Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla. Prior to his appointment as Chief Scientific Officer at Kite Pharma in 2011 and then Vice President of Translational Medicine, Dr. Bot served in various senior R&D management positions at MannKind Corp and Alliance Pharmaceutical Corp.
Day Two
Wednesday 26th February 2020
9:30 am | Determinants of Durable Response Upon Treatment with Axi-cel
Alessandra Cesano
Chief Medical Officer
Alessandra Cesano, MD, PhD has recently joined ESSA as Chief Medical Officer. Previously she has been the Chief Medical Officer of NanoString Inc from July 2015 until June 2019 where she focused in the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response/resistance. Prior to joining NanoString, Dr. Cesano was Chief Medical Officer at Cleave Biosciences, Inc. and before then she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc., where she built and led the R and D group, while providing the overall clinical vision for the organization. Between 1998 and 2008, Dr. Cesano held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Early in her professional career Dr. Cesano spent 12 years conducting research in tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center connected with the University of Pennsylvania. She also holds membership in several professional and scientific societies including ASCO, ESMO, ASH, EHA, AACR and SITC. In the latter she serves as co-chair in the SITC Industry Committee, Associate Editor for the Biomarker section of JITC and is an active member of the SITC Biomarker Working Group. Over her careers she has been an author on over 100 publications. Dr. Cesano received an MD summa cum laude, a Board Certification in Oncology and a PhD in Tumor Immunology from the University of Turin.
Ali Mohamad
Vice President CMC
Ali Mohamed, PhD, Vice President, CMC, Immatics US Inc. Formerly the senior director of manufacturing operations/ manufacturing development at Caladrius PCT (Now Hitachi Chemical Advanced Therapeutics Solutions). Dr. Mohamed has nearly 20 years of experience in process development and GMP manufacturing of regenerative medicine, cell and gene therapy products at various CMOs and clinical stage companies including Lonza, Osiris Therapeutics, and AlloCure. The speaker holds a PhD in Molecular Pharmacology from Medical College of Ohio and postdoctoral fellowship in neuroscience and neurobiology from the Georgetown University.
Alice Brown
Vice President of Research
GammaDelta Therapeutics
Alice Brown is Vice President of Research at GammaDelta Therapeutics leading a team developing Vd1 gd T cells as a novel cell therapy approach for tackling solid tumours and hematologic malignancies. Prior to GammaDelta, Alice spent 7 years with PsiOxus Therapeutics as Director of Biology. Alice has a PhD in Biochemistry and carried out her post-doctoral research in Prof. Dan Davis' Lab at Imperial College London studying the basic biology and interactions of human NK cells
Annie Hubert
Senior Director, Section & Public Policy
Alliance for Regenerative Medicine
Blake Aftab
Vice President and Head of Preclinical Science and Translational Medicine
Atara Biotherapeutics
Blake T. Aftab, PhD is Vice President and Head of Preclinical Science and Translational Medicine at Atara Biotherapeutics. Dr. Aftab leads cell therapy discovery, research, and translational evaluation for off-the-shelf cell therapies covering oncology, infectious disease, and autoimmune conditions. He has over 15 years experience in academic, biotech and pharmaceutical industries developing multiple therapeutic modalities including small molecule, biologics, antibody-drug conjugates and cell therapies. He conducted his doctoral training in Pharmacology and Drug Development at The Johns Hopkins University School of Medicine and received his Bachelors in Pharmacology and Drug Discovery from The University of California, Santa Barbara.
Cedrik Britten
VP & Head of Oncology Cell Therapy Research Unit
Cedrik is a physician and immunologist working in the field of Immuno-Oncology since 1998. From 2001 to 2008 he worked in haematology and blood transfusion departments and conducted translational research on tumour-specific T cells and anti-cancer vaccines trials. Cedrik joined BioNTech AG in 2008 where he drove the company's growth to a mid-sized enterprise of 250 FTE. As Vice President R&D his translational team was the first to test highly personalized mutanome vaccines in melanoma patients. Cedrik joined GSK in 2015 and is heading the Oncology Cell Therapy Research Unit (OCT RU). The current R&D activities cover the non-clinical and clinical development of TCR-T & CAR-T cells, technologies to enhance patient benefit of engineered lymphocytes in solid cancer, innovative ways to supply autologous cell products, and the discovery of new targets for CAR-T cell approaches.
Deborah Morrison
Principal Scientific Advisor
National Institute for Health & Care Excellence
Delfi Krishna
Director, Strategy, Portfolio, Operations, Cell & Gene Therapy Platform
Dolores Schendel
Since the 1970s, Prof. Dr. Dolores Schendel has been researching T cells and their abilities in immunotherapy and has accompanied the scientific and therapeutic turn of era in this field. Prof Schendel served as a University Professor for Immunology at the Ludwig-Maximilian-University, is the author of more than 200 scientific publications, has spent several decades as a scientific review board member in various research organizations such as the German Research Foundation, German Cancer Aid and the European Research Council among others. She is a recipient of the German Federal Order of Merit and the Bavarian Order of Merit and received the 'Deutsche Krebshilfe Preis', the award of the German Cancer Aid. From 1998 - 2013, Prof Schendel was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Following this, she founded the Trianta Immunotherapies GmbH (today "Medigene Immunotherapies GmbH). With the acquisition by Medigene in 2014, Dolores Schendel became Chief Scientific Officer and, in 2016, also the CEO of the company.
Day One
Tuesday 25th February 2020
8:30 am | Industry Leader's Fireside Chat
Francesco Marincola
Chief Scientific Officer
Refuge Biotechnologies
Dr. Marincola is Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California. He was previously Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications and Clinical and Translational Medicine. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning author of The Wise Men of Pizzo and Cat Behind the Window.
Jen Renwick
VP, Development Operations
Jen Renwick is Vice President, Development Operations at Adaptimmune LLC, a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. She joined the company in 2016 to lead the Clinical Science and Operations function responsible for trial planning and execution. Jen was instrumental in building the group in the US and EU and initiating Adaptimmune's first TCR trials in Europe. She has also provided operational oversight and management of the Development function and the integration of Research and Development. An Oncology Pharmacist by training, she has over 25 years' experience in the biopharmaceutical sector specialising in clinical development. Prior to Adaptimmune, she was Head of Global Study Management at Amgen with oversight of Phase 1b-4 trial execution across all therapeutic areas. She was involved in several Regulatory filings of unique oncology products, including treatments for solid tumours and hematologic malignancies, as well as supportive care agents. During her time at Amgen she also gained Medical Affairs and commercial launch experience at Amgen Europe's headquarters in Switzerland and led the clinical integration of several small immuno-oncology companies post acquisition.
Hong Ma
SVP, Clinical Development
CARsgen Therapeutics
Dr. Hong MA is a clinical oncologist with 20 years of cancer immunotherapy and orphan drug development experience, including over 15 years of pharmaceutical industry experience. He has in-depth experience in cellular therapy programs in the U.S. and EMA region with 8 IND & CTA approvals. Before joining in CARsgen, he served as the senior medical director & senior director of clinical development at Immatics Biotechnologies GmbH. Prior to this role, he was the director of clinical development at Bellicum Pharmaceutical, Inc. and was the director of clinical operation at Endocyte Pharmaceutical (now the part of Novartis Oncology).
Jacquelyn Awigena-Cook
Associate Director, Regulatory Policy and Intelligence
Jacquelyn is currently Associate Director, Regulatory Policy and Intelligence at Celgene. She has over 12 years of experience in the pharmaceutical industry managing projects, designing processes and leading initiatives aimed at driving regulatory policy advocacy activities that support development of innovative medicines and assessing the impact of regulatory changes on strategy, operations and compliance. Her current area of focus is on regulatory policies impacting Advanced Therapy Medicinal Products (ATMPs) and delivering key regulatory intelligence insights to support project teams in the Hematology – Oncology disease area. She also spent several years' focusing on the global pharmacovigilance regulatory environment.
John Johnston
Clinical Assessor
John Maher
Immunology Consultant, King's College London / CSO
Leucid Bio
Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and the Royal Free NHS Foundation Trust, at Barnet Hospital.
Day Two
Wednesday 26th February 2020
8:45 am | Chair's Opening Remarks
Kai Pinkernell
Dr. Kai Pinkernell is responsible for the clinical advancement of Medigene's immunotherapy platforms since February 2016. In April 2018, he was appointed to the Executive Management Board of the Company as Chief Medical Officer (CMO) and Chief Development Officer (CDO). Dr. Pinkernell has acquired long-term expertise in worldwide clinical development, clinical marketing and clinical sales as well as automation and GMP production of cellular therapies. Prior to joining Medigene, he held leading positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as Global Head of Clinical Business and Head of Clinical Development. Previously, Dr. Pinkernell was with Cytori Therapeutics Inc., San Diego, USA, as Senior Director of Regenerative Cell Technology.
Lothar Germeroth
Juno Therapeutics
Lothar Germeroth is Senior Vice President at Juno Therapeutics Inc., a Celgene Company and Managing Director at Juno Therapeutics GmbH, and joined Juno through the acquisition of Stage Cell Therapeutics in May 2015. Dr. Germeroth has over 25 years of management experience in biotechnology. Dr. Germeroth served as the CEO at IBA GmbH and the COO at Stage Cell Therapeutics GmbH, and served eight years as CEO in three different German Biotech companies (Jerini BioTools GmbH, Chemotopix GmbH, Cytos Proteome Therapeutics GmbH) and as Chief Business Officer at Cytos Biotechnology AG in Switzerland. Dr. Germeroth studied chemistry in Frankfurt/Main and obtained his PhD in Biochemistry in the department of Nobel Prize Laureate Professor Hartmut Michel at the Max-Planck Institute of Biophysics in Frankfurt.
Gary Pigeau
Director, Centre for Advanced Therapeutic Cell Technologies
GE Healthcare Life Sciences
Gary Pigeau received his PhD in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined the Centre for Advanced Therapeutic Cell Technologies (CATCT), a collaboration between GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM), in 2016. He currently serves as Director of the CATCT facility in Toronto, Ontario. In this role, Gary focuses on biology support for new product introductions, internal technology development projects, and contract process development services for cell and gene therapy.
Day Two
Wednesday 26th February 2020
9:00 am | CAR T Therapies: Process Development and Manufacturing Readiness
Michael Leek
Chief Executive at TC BioPharm, Michael has 28 years' experience in regenerative medicine, during which he progressed 9 different cell-based products from laboratory into clinic. As co-founder, he was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. He has extensive GMP manufacture, clinical, regulatory and logistic expertise, he has directly raised over £50m in equity and grant funding.
Michael Lehmicke
Director, Science & Industry Affairs
Alliance for Regenerative Medicine
Michael Lehmicke, ARM's Director of Science and Industry Affairs, is responsible for shaping and leading science and manufacturing initiatives at ARM, as well as leading ARM's science and technology-related member committees and task forces. Michael has more than 20 years of R&D experience in biomaterials, medical devices and regenerative medicine. He has led product development teams for class II devices, human cell and tissue-based products, and drug/device combination products. He is a creator and an inventor with multiple U.S. patents to his name. Michael has a MSc in Biomedical Engineering, with a focus on tissue engineering, from Drexel University.
Gisèle Deblandre
Gisèle Deblandre, PhD, is Chief Scientific Officer at MaSTherCell. She is an experienced cell and developmental biologist with extensive experience in cell therapy. She has worked for the last 8 years at MaSTherCell (Belgium) where she has been heading work on process and analytical assay development for cell and gene therapies at all phases of their clinical development. She has also set up and headed Project Management to support technology transfer and GMP manufacturing. Previously with Celyad (Belgium) she headed the development of an autologous cell therapy for the treatment of heart failure and at the laboratory of Paediatric Hepatology at the University of Leuven, the development of a hepatic progenitor-based therapy for liver diseases. Her career spans 22 years in R&D in life sciences, with a strong expertise in cell biology and mechanisms of cell differentiation. She has a PhD in Molecular Cell Biology from the University of Brussels and she then specialized in Developmental Biology at the Salk Institute (San Diego, California).
Stefan Ibing
Attorney at Law
Head of Legal CEE Pharma
Lead lawyer and member of the management-team of Novartis Pharma Services AG: - legal entity which exports the Rx-drugs of Novartis´ Innovative Medicines Division (Pharmaceuticals and Oncology) out of Switzerland into more than 80 countries worldwide by export-sales to 3rd party distributors. Furthermore this entity operates app. 35 Representative Offices. - main geographic areas: Eastern Europe (incl. small EU-countries), Middle East, Africa and Asia - started supporting this export-entity in 2012 as dedicated Senior Legal Counsel without direct reports, gradually built up a new operational legal department for this entity with currently 5 lawyers and a paralegal as direct reports - general-counsel-like scope of activities, including all major commercial contracts, country-setup analyses, investigations, market access topics, launch of Novartis` gene therapies in EU-countries (e.g. Kymriah CAR-T therapy and Luxturna) etc. - very close interactions and teamwork with a network of regional and cluster lawyers for the geographies Eastern Europe, Middle East, Africa and Asia.
Kamal Veer Saini
Senior Medical Director, Oncology
► Kamal Veer Saini, a board-certified medical oncologist, is a Senior Medical Director, Oncology at Covance. He is based in Brussels, Belgium, and contributes to medical strategy in the oncology area and client engagement on asset development and all related aspects of medical and scientific execution. ► He has more than 15 years of experience in academia and industry, having held numerous posts of increasing seniority across all phases of clinical drug development in various cancer types (solid tumors as well as hematological malignancies) with both regional and global responsibility. His publications include numerous articles in the areas of breast cancer, clinical trials, molecular oncology, biomarkers, global oncology, policy, etc.. ► Areas of interest: Immuno-oncology, cell and gene therapy, global strategic clinical drug development, breast cancer, lung and other thoracic cancers, molecularly defined cancers, biomarkers, artificial intelligence in oncology.
Qasim Rafiq
Associate Professor, Cell & Gene Therapy Bioprocessing
University College London
Dr Qasim Rafiq is an Associate Professor at University College London in Cell and Gene Therapy Bioprocessing. He is a multidisciplinary engineer and currently leads a research portfolio of >£3M focusing on the bioprocessing, automation and biomanufacture of ATMPs. . He has specific interest in addressing the large-scale manufacturing challenges and enhancing process and product understanding to enable successful translation from the laboratory to the clinic. He is both a Chartered Engineer (CEng) and Chartered Scientist (CSci) and sits on multiple scientific and engineering committees including the BIA's Cell and Gene Therapy Advisory Committee and the BSI's Biotechnology Standards Group.
Reuben Benjamin
Consultant Haematologist
Kings College Hospital NHS
Lead lawyer and member of the management-team of Novartis Pharma Services AG:
- legal entity which exports the Rx-drugs of Novartis´ Innovative Medicines Division (Pharmaceuticals and Oncology) out of Switzerland into more than 80 countries worldwide by export-sales to 3rd party distributors. Furthermore this entity operates app. 35 Representative Offices.
- main geographic areas: Eastern Europe (incl. small EU-countries), Middle East, Africa and Asia
- started supporting this export-entity in 2012 as dedicated Senior Legal Counsel without direct reports, gradually built up a new operational legal department for this entity with currently 5 lawyers and a paralegal as direct reports
- general-counsel-like scope of activities, including all major commercial contracts, country-setup analyses, investigations, market access topics, launch of Novartis` gene therapies in EU-countries (e.g. Kymriah CAR-T therapy and Luxturna) etc.
- very close interactions and teamwork with a network of regional and cluster lawyers for the geographies Eastern Europe, Middle East, Africa and Asia.
Tol Trimborn
Experienced Venture Partner with a demonstrated history of working in the venture capital and private equity industry. Strong information technology professional skilled in Business Development, Cell Biology, Biotechnology, Business Strategy, and Biochemistry.
William Cao
Dr. Wei (William) Cao is the founder, chairman and CEO of Gracell Biotechnologies Group. Through external partnership and in-house R&D effort, Gracell has been rapidly progressing with novel CAR-T programs and regenet stove medicine programs. Dr. Cao has over 30 years of professional experience in scientific research, products development and startups. He was the co-founder and CEO of a Nasdaq listed cellular therapy company. Prior to his ventures, Dr Cao served as Technical Manager for Bayer Asia Pacific, and China General Manager of Affymetrix, a world leader in genetic analysis. Dr. Cao earned a Bachelor's degree in Medicine from Fudan University and a PhD degree in Immuno-Pharmacology from Medical College of Virginia. He has extensive research experience in immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. He is the inventor of more than 70 patents in the field of stem cell and CAR-T technologies.
Yannick Bulliard
Director, Translational Development
In 2016, Yannick Bulliard joined Immatics US, Inc. as Director Product Science, where he established the Department's core activities in process development, development of immunoassays and quality control. Since 2017, Dr. Bulliard is leading the translational development of ACTallo®, Immatics' allogeneic cellular therapy platform based on γδ T cells. Prior to Immatics, Dr. Bulliard was a project lead for several preclinical assets in Immuno-Oncology at Amgen, CA. He obtained his Ph.D. from the EPFL, Switzerland and went on to pursue a postdoctoral fellowship at Novartis in Cambridge, MA.
Aura Mackenzie
Senior Director, AVES, Market Access
bluebird bio
After over a decade in global pricing and market access consulting for biotech and big pharma, Aura shifted industry-side after realizing that nothing fired her up more in drug development than the promise of cell and gene therapy. Aura's role at bluebird is early evidence and access strategy planning for the oncology and severe genetic disease portfolio. Fun fact: Aura is a dab hand at ultimate frisbee and plays nearly every weekend, rain, snow, or shine. While she's not as competitive as she once was, her vacations are still planned around frisbee tournaments more often than they're not!
Valeria Judkowski
Senior Director, Quality Assurance, Site Qualification
Kite, a Gilead Company
Valeria Judkowski is the Senior Director, Quality Assurance, Site Qualification at Kite, a Gilead Company. In this role, she oversees the European regional team responsible of the commercial qualification of apheresis and treatment centers to work with Yescarta®, one of the first CAR T therapies to be developed, manufactured and commercialized. Prior to Kite, Valeria oversaw the areas of technology transfer, GMP manufacturing and quality control for a phase III autologous dendritic cell based therapy as part of the Immunocellular Therapeutics Ltd pipeline in Europe. In previous years, Valeria was an Assistant Professor in Immunology at The Torrey Pines Institute for Molecular Studies, La Jolla, California. She focused most of her scientific career on the field of Antigen Discovery, working mainly on the regulation of the T cell immune response for the development and evaluation of active immunotherapies in Oncology and Autoimmunity. Valeria studied at the University of Sciences of Buenos Aires, Argentina, from which she received a Master Degree in Molecular Biology and a PhD in Immunology.
Pippa Gledhill
Research Analyst
Beacon Targeted Therapies
Day Two
Wednesday 26th February 2020
10:00 am | CAR-TCR Landscape Review
Jingyi Xiang
Director of Scientific Alliances
Eureka Therapeutics
Jacob Plieth
Senior Reporter
Vantage Analysis
Jacob has 21 years' experience of writing about healthcare, and joined Vantage in 2012 from Edison Investment Research, where he spent five years as an equity research analyst.
He has also worked at Dow Jones and the Wall Street Journal. A biochemist by training, Jacob has spoken about pharmaceuticals and other topics on the BBC World Service and News 24, as well as contributing to various publications including Investors Chronicle and Mednous.
Day One
Tuesday 25th February 2020
8:30 am | Industry Leader's Fireside Chat
Anil Singhal
President & CEO
Adicet Bio
Dr. Singhal has served as Adicet Bio's President and Chief Executive Officer and a member of the Board of Directors since May 2019. He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of their Abbvie-Redwood City, California site. During his tenure at AbbVie, he oversaw the global regulatory approval of Empliciti in multiple myeloma. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases. Dr. Singhal has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington. He serves on the Board of Directors of TriSalus Inc.
Richard Zajicek
Medicine and Process Delivery Leader
Omar Ali
Visiting Lecturer, Value Based Pricing & Former Adviser to NICE
University of Portsmouth
Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network. Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, was an Editorial Content Adviser to Guidelines, and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology.
Vicki Coutinho
VP, Regulatory Affairs & Quality
GammaDelta Therapeutics
Manel Juan
Head of Immunotherapy Platform
Barcelona Children's Hospital and Hospital Clinic
Andre Choulika
Day One
Tuesday 25th February 2020
8:30 am | Industry Leader's Fireside Chat
Eric Alonzo
Senior Scientist, Cell Analytics
bluebird bio
Michal Besser
Head of Laboratory, Director
Sheba Medical Center
Zhifen Yang
Senior Scientist
Refuge Biotech
Day Two
Wednesday 26th February 2020
9:45 am | Contextual Regulation of CAR T Function In Vivo
Stefano Baila
Director of Operations and Business Development
Dalip Sethi
Manager, Senior Scientist, Cell Therapy Technologies
Terumo BCT
Dalip Sethi currently serves as the scientific development lead for the Cell Therapy Technologies portfolio at Terumo BCT. He holds a doctorate degree and conducted post-doctoral studies at Thomas Jefferson University, School of Medicine. Prior to Terumo BCT, Dalip was engaged in the development of technologies & methods for use in autologous cell therapy applications. Throughout his career, Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications.
Day One
Tuesday 25th February 2020
9:30 am | Driving Automation in Cell Therapy Manufacturing
Nicolas Danzenbaecher
Senior Product Manager
Miltenyi Biotec
Will Singleterry
Director, Collaborations, Cancer Immunology Team
Fiona Thistlethwaithe
Medical Oncology Consultant & Director
Lindsey Clarke
Head of Cell & Gene Therapy EMEA
Bio-Techne Corporation
Mark Flower
VP, Business Development
Be The Match BioTherapies®
Oezlem Anak
VP, Global Program Head CAR-T
Helen-Tayton Martin
Dr. Helen Tayton-Martin has served as our Chief Business Officer since March 2017, having formerly served as our Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. As our CBO, Dr. Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline (LSE/NYSE: GSK) ("GSK").
Day One
Tuesday 25th February 2020
8:30 am | Industry Leader's Fireside Chat
Peggy Sotiropoulou
Director, Research & Development
Peggy Sotiropoulou joined Celyad in 2017. As Director of the R&D department, she leads a broad-ranging internal research program that aims to develop new strategies in CAR T cell design to target haematological and solid malignancies. Prior to Celyad, Peggy spent 17 years in Academic research in oncology and immunooncology. Before moving to industry, Peggy was associate Professor in the Université Libre de Bruxelles, in Brussels, Belgium, leading research in fundamental oncology and published landmark papers in top tier scientific journals. The aim of Peggy in Celyad is to translate cutting-edge research and innovation into actual treatments for patients.
Michael Koslowski
GammaDelta Therapeutics
Michael joined GammaDelta in 2018 from Mission Therapeutics where he was EVP Research & Development and Chief Medical Officer, responsible for developing Mission's pipeline of deubiquitinating enzyme inhibitors. Prior to joining Mission Therapeutics Michael was VP Clinical Sciences & Early Development at Glenmark Pharmaceuticals where he led all clinical activities to progress Glenmark's innovative drug portfolio. Before, Michael formed and managed a new group of Translational Medicine Experts at Boehringer Ingelheim to support and drive early drug development activities across all therapeutic areas at BI. Michael was Group Leader New Targets & Antibody Development at Ganymed Pharmaceuticals and a Principal Scientist in Experimental & Translational Oncology at the University of Mainz with focus on cancer drug target identification and development of novel immunotherapeutics.
Day One
Tuesday 25th February 2020
8:30 am | Industry Leader's Fireside Chat
Mythili Koneru
SVP, Clinical Development
Marker Therapeutics
Mythili Koneru, M.D., Ph.D. is Senior Vice President of Clinical Development at Marker Therapeutics, a clinical-stage company specializing in the development of T cell-based immunotherapies for treatment of hematological malignancies and solid tumors. In this role, she is responsible for clinical development strategy, clinical study design, and medical oversight of the Company's therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology. In her previous role, Dr. Koneru designed early-stage clinical trials for hematologic and solid tumor malignancies and was instrumental in developing clinical trial protocols, serving as medical lead for trial conduct. Prior to Eli Lilly, Dr. Koneru completed her oncology fellowship in the laboratory of Dr. Renier Brentjens at Memorial Sloan-Kettering Cancer Center, where she developed adoptive T cell therapies in both leukemia and solid tumor malignancies in early phase clinical trials.
Jo Tomlins
Clinical Services Manager/ Nurse Clinician
The Christie NHS Foundation Trust
Jo Tomlins (RN, BSc (Hons), MSc, NMP) has worked as a Nurse Clinician in haematology oncology since qualifying as an advanced nurse practitioner in 2008. In 2015 she took on a combined role as Nurse Clinician and Clinical Services Manager for haematology, teenage and young adults (TYA) and endocrinology and maintained a clinical focus on acute lymphoblastic leukaemia and haematological malignancies in TYA patients. Jo has worked at the Christie since 2002 in haematology as a ward nurse and subsequently research/specialist nurse prior to doing her masters in advanced practice. Jo has an in depth knowledge of haematological malignancies and uses advanced clinical skills in the management of patients. Jo is also the clinical lead on both the principles of haematology oncology and CART masters modules at The University of Manchester where she is an honorary clinical fellow. As an experienced haematology nurse and clinical services manager Jo has delivered on several service developments such as setting up ambulatory care and more recently CART therapy for this patient group. She is driven to provide high quality care to oncology patients through her clinical, education and leadership roles.
Kimberly Freeman
Vice President, Global Commercial Head, Commercial Strategy
Kimberly Freeman is the Vice President, Global Commercial Head, Commercial Strategy at Adaptimmune LLC, a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. Kimberly joined Adaptimmune in 2016 to lead global commercial strategy and market preparation for the successful development and regulatory approval of these novel therapeutics. Specializing in oncology drug development and commercialization for over 25 years, Kimberly has worked within the biopharmaceutical industry in disciplines across research, clinical development, new product planning, marketing, sales and market access. Previously she served as head of Oncology National Accounts at Boehringer Ingelheim Pharmaceuticals where she launched their first lung cancer product and companion diagnostic. Prior to that, she spent 14 years at GlaxoSmithKline where she launched five unique oncology products, including treatments for solid tumors and hematologic malignancies, as well as supportive care agents. Kimberly holds a master's degree in Biology from Cornell University.
Scott Carter
VP, Field Operations and Customer Relations
Cindy Jung
Director of Vector Process Development in the Cell and Gene Therapy Platform
Cindy Jung is the Director of Vector Process Development in the Cell and Gene Therapy Platform at GSK, and is responsible for developing robust and scalable viral vector manufacturing processes. Cindy has previously held roles at GSK leading teams that focused on alternative manufacturing processes for biopharms, and at Merck supporting downstream development of viral vaccines. She obtained her Ph.D. in Biomedical Engineering from the joint program at Georgia Tech and Emory University.
Lisa Kinsella
Head Legal Biologics, Cell & Gene
Lisa Kinsella is Head Legal Biologics, Cell & Gene at Novartis Technical Operations, and provides legal support for all aspects of manufacturing, supply chain, quality and technical development of biologics and advanced therapies. Lisa joined Novartis in 2012 and since then has held positions of increasing responsibility within Novartis Legal. Prior to joining Novartis, Lisa practiced law in the life sciences practice of Arthur Cox, one of Ireland's leading commercial law firms where she advised clients in the pharmaceutical, biotech and medical devices fields on transactional, regulatory and commercial contracting matters. Lisa is qualified in Ireland, England & Wales and is admitted to the New York Bar.
Steven Shamah
Senior Vice President and Head of Research
Obsidian Therapeutics
Dr. Steven Shamah joined Obsidian Therapeutics in September 2016 as Senior Vice President and Head of Research where he leads a dynamic team towards the discovery and development of next generation cell and gene therapeutics. Previously, Steve served as Head of Scientific Operations for the Cell and Protein Sciences group at Juno Therapeutics and, prior to that, as VP of Cell Biology at X-Body Biosciences. In addition, Steve has served in various management and scientific leadership roles at SRU Biosystems, Archemix, Hydra Biosciences and Phylos, with a particular focus on biologics discovery using in vitro display technologies.
Ryan Cawood
Founder and CEO
Oxford Genetics
Ryan founded the company in 2011 with the aim to revolutionize DNA design, optimisation and assembly to enable molecular engineering to fulfil its promise in synthetic biology and medicine. Ryan has a first class degree in Genetics and a Ph.D. from Oxford University. He is an experienced genetic engineer with extensive knowledge and practical insight working with bacterial, botanical and mammalian recombinant expression systems. Ryan's research interests in synthetic biology and molecular engineering include vaccines and treatments for infectious diseases and cancer. He was inspired to create Oxford Genetics after observing that inefficient DNA design and assembly often limit scientific progress.
Laurence Cooper
Ziopharm Oncology
Laurence joined Ziopharm Oncology as chief executive officer in 2015 after Ziopharm and Intrexon Corporation together licensed technology for a non-viral approach for genetically modifying T cells from MD Anderson Cancer and the University of Minnesota. This technology is designed to reduce the cost and complexity of genetically modified T cells. Prior to joining Ziopharm, Laurence was a tenured Professor at MD Anderson with joint appointments in the Division of Pediatrics and Department of Immunology. There, he served as Section Chief of Cell Therapy at the Children's Cancer Hospital and helped lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. He remains a visiting scientist at MD Anderson. Laurence has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and he completed his training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.
Marleen Van Loenen
Director, Non-Clinical Development
I am responsible to manage and oversee non-clinical development of TEGs: abT cells engineered to express a defined gamma/delta TCR. Gadeta's preclinical engine encompasses different in vitro and in vivo models using tumor and healthy cell lines as well as primary material to test Gadeta's lead product TEG002 as well as new leads for safety and efficacy. Results are written into study reports, to enable IND submission. To optimize and speed up preclinical development, I oversee collaborations with companies and universities to exchange knowledge, models and materials. Furthermore, I am on two Joint Project Teams (Research & Translational Science) with collaborator Kite.


text: WHAT IT IS: Argan Oil is known as the "liquid gold" because it's packed with Omega-6 fatty acids, linoleic acid and antioxidants, Luseta Argan Oil Collection helps hair restore, enhance and grow. The natural moisturizer will help repair, dry, brittle and damaged hair from blow drying, flat ironing and sun exposure. WHAT IT DOES: Free of sulfates, phosphates, and parabens No animal testing Tames and conditions the look of your hair Protects hair from environmental damaged Eliminates frizz and restores shine and softness Ideal for all hair types HOW TO USE: Apply a small amount to clean, damp hair and style as usual, or smooth on dry hair to tame and add shine. KEY INGREDIENTS: Argan Oil: Bursting with nutrients such as fatty acids and vitamin E to treat dry and damaged hair and revitalize strands with shine and volume, while nixing flyaways and repairing split ends Linseed Oil: High in Omega 3 fatty acids and Vitamin E, which helps prevent hair loss and minimize dandruff to foster strong, shiny, and healthy hair growth Almond Oil: Rich in magnesium, zinc, and calcium to strengthen hair growth and prevent hair loss, as it protects against environmental pollutants and nutritional deficiencies INGREDIENTS: CYCLOPENTASILOXANE, DIMETHICONE, DIMETHICONOL, ARGANIA SPINOSA KERNEL (ARGAN) OIL, LINUM USITATISSIMUM (LINSEED) SEED OIL, C12-15 ALKYL BENZOATE, SWEET ALMOND OIL, OLEA EUROPAEA OIL, BENZOPHENONE-3, TOCOPHERYL ACETATE, PARFUM, BHT, CI 26100, CI 47000, HYDROLYZED KERATIN, HYDROLYZED KERATIN PG-PROPYL METHYLSILANDDIOL, HYALURONIC ACID, ALOE BARBADENSIS LEAF JUICE


text:
- Free color and chair part customisation (Write down color codes in "Customer Remark")
- FREE DELIVERY for purchasing any 5 or more products
- Genuine OEM and Superb Quality products manufactured in Malaysia
- 1 year of warranty
Product Specifications:
- Heavy-duty material
- Multi Density Foam Cushioning: 55kg/m3
- Adjustable back-rest recline tension
- Back-rest recline angle locking feature
- Adjustable headrest height and angle
- Adjustable chair height with pressure pump
- Adjustable lumbar support angle
- 360 degree tilting
- Breathable mesh with cooling effects
- Standardised backrest design to support spine
Prime tier specification: Chrome steel adjustable height armrest, chrome steel chair base
Silver tier specification: Fixed position armrest, acrylic chair base
Product Features:
Width: 66cm, Height: 124cm, 19kg
Free skin and color customization:
Free chair parts customization:
The process of creating Premium and Perfection:
Unable to find the design of chair that you looking for? Contact us now and we may create the chair you want for you!
018 662 8581
016 237 2315
012 271 8581


text:
Universal Credit
Hello everyone!
I hope you're all welll.
Does any of you gets universal credit?if you do get which are the disadvantages?
What do you think of this?
carol50gartland2 years ago
It ok
One of the UK's largest deal hunting communities
Join for free to get genuine deals, money saving advice and help from our friendly community
Kelsey, Tom
& Deepak
& Deepak


text:
another FABULOUS all nighter with a hard deadline LOL
the sherry fairyTag
#asksherryfairy #500ReasonsWhy I #amwriting #SherryCarroll
Feeling Restless? #FollowtheFairy Let's take off for a quick trip to Rio? with a detour down memory lane
It's only a whimsical notion…But then again , I just might
Still up? #FollowtheFairy No worries Its just another full moon #TheKinks
Don't fret and toss and turn. If you cant sleep anyway get up and do something you enjoy. Its always the darkest before the dawn.
Make a magical moon garden
I love the night. No phones or doorbells ringing. None of those pesky people trying to (SHUDDER) TALK TO YOU lol and get on your nerves and get under your feet when you have things to think about and STUFF TO DO
It will be over soon enough. So don't waste it worrying about things you cant do a thing about right now.
It will be clear in the light of day. I promise
Had a rough day? #FollowtheFairy Me too. But its finally over So I went here…
And at least it is over , for now. I hope . Tomorrow can only be better right? because it couldnt be worse. thats' what they say. But what i want to know is who are these THEY who keep saying such stupid things? it can ALWAYS GET WORSE lol Lets just hope it doesn't. Wishing you love, peace, and joy tonight on the dark side of the moon


text:
Saturday September 7, 2019 (RBB NEWS) – MOGADISHU "Media organisations have condemned the blocking of two websites in Puntland and Somaliland terming the move an affront to press freedom and denying the public access to information.
The International Federation of Journalists (IFJ) and National Union of Journalists (NUSOJ) condemned the blocking of Puntland Times and Hadhwanaag News calling it 'an attack to press freedom'.
"The blocking of the website has denied many people in Somaliland access to information which is tantamount to a denial of basic human rights, including freedom of expression and press freedom," said Omar Faruk Osman, NUSOJ Secretary General.
Authorities in Puntland announced September 3 that it was shutting down Puntland Times but did not cite reasons.
Puntland Times editor Farah Abdulkadir Geylan quoted by NUSOJ said he had not been informed of the reasons for the closure of the website by the government but there were reports it could be linked to a story carried by the news site about ministry of information salary delays.
In Somaliland, a court declared Hadhwanaag News be blocked for 'baseless" articles and interviews damaging the reputation of the Central Bank governor, Ali Ibrahim Jama 'Baghdadi', and accusing him "misuse of public funds".
IFJ called on authorities in Puntland and Somaliland to respect press freedom and stop stifling the media. "We condemn the blockade of news websites in Somaliland and Puntland regions.
The IFJ urges authorities to respect freedom of information and stop harassing critical media. The blockade of Hadhwanaag News and Puntlandtimes.com must be lifted."